SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JANUARY 8, 2001
CIPHERGEN BIOSYSTEMS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 000-31617 33-059-5156
(STATE OR OTHER JURISDICTION OF [COMMISSION FILE NUMBER] (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER)
6611 DUMBARTON CIRCLE
FREMONT, CA 94555
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(510) 505-2100
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
ITEM 5. OTHER EVENTS
On January 8, 2001, Ciphergen Biosystems, Inc. issued a press release
announcing that its preliminary revenue forecast for the fourth quarter ending
December 31, 2000, will be approximately $3 million, or approximately 10-15%
below previous company expectations. The press release is attached as Exhibit
99.2 to this Form 8-K.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
EXHIBIT
NUMBER DESCRIPTION
- ----------------- -------------------------------------------------------------------
99.2 Ciphergen Biosystems, Inc. Press Release issued January 8, 2001.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CIPHERGEN BIOSYSTEMS, INC.
(Registrant)
Date: January 8, 2001 By: /s/ William Rich
---------------------------------------
William E. Rich
President and Chief Executive Officer
-2-
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
- ----------------- -------------------------------------------------------------------
99.2 Ciphergen Biosystems, Inc. Press Release issued January 8, 2001.
-3-